Rat Nogo-A aa 2-172 Antibody Summary
Glu2-Val172
Accession # Q9JK11
Customers also Viewed
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data

Detection of Rat Nogo-A by Western Blot RT-PCR analysis and western blot analysis of Nogo-A mRNA and protein production in the hippocampus after TBI. (A) The PCR products from Nogo-A transcription after TBI with the yield of actin as an internal control. The sampling times after TBI are shown on the top (n = 4 in each group). (B) Quantification of Nogo-A mRNA expression by semiquantitative densitometry in conjunction with AlphaEase software (Alpha Innotech Corp.). (C) Time course of Nogo-A protein production after TBI, internal control: beta -actin. Times shown on top represent hours after injury. (D) Quantification of Nogo-A protein by semiquantitative densitometry in conjunction with AlphaEase software (Alpha Innotech Corp.). The data are presented as ratios related to the sham group. Bars represent the means ± SEM values. *p < 0.05 is considered significantly different from sham values using the Mann–Whitney U test. SEM, standard error of the mean; TBI, traumatic brain injury. Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-121), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Rat Nogo-A by Western Blot Effects of Nogo-A irrelevant control and antisense oligodeoxynucleotides on hippocampal Nogo-A expression after TBI. (A) RT-PCR analysis of Nogo-A mRNA transcription level. Actin transcription was used as an internal control. (B) The expression of Nogo-A was quantified by densitometry and compared with the data from rats injected with saline (sham), which was normalized to 100%. (C) Western blot analysis of Nogo-A protein level; beta -actin was used as an internal control. (D) Quantification of Nogo-A protein by semiquantitative densitometry in conjunction with AlphaEase software (Alpha Innotech Corp.). The data are presented compared with the sham group. The data are represented as the means ± SEM values (n = 6). *p < 0.05 was considered significantly different from the sham value using the Mann-Whiney U test, and #p < 0.05 was considered significantly different from the TBI with sense values using the Mann-Whiney U test. SEM, standard error of the mean; TBI, traumatic brain injury. Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-121), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Rat Nogo-A by Western Blot Effects of indomethacin administration on Nogo-A expression. Animals were in one of four groups: sham (no TBI), TBI treatment (TBI eight hours), TBI combined with vehicle administration (TBI + vehicle), and TBI combined with indomethacin administration (TBI + indomethacin). (A) RT-PCR analysis of the expression of Nogo-A among different groups along with the analysis of beta -actin transcription as an internal control. (B) Quantification of Nogo-A expression. (C) Western blot analysis of the expression of Nogo-A among different groups along with the analysis of beta -actin as an internal control. (D) Quantification of Nogo-A expression. Bars represent means ± SEM values (n = 5). *P <0.05 is considered significantly different from the sham value using the Mann–Whitney U test and #P <0.05 is considered significantly different from the TBI value using the Mann–Whitney U test. SEM, standard error of the mean; TBI, traumatic brain injury. Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-121), licensed under a CC-BY license. Not internally tested by R&D Systems.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Nogo-A
Nogo-A, also known as Reticulon-4, is the longest of four splice variants of Nogo. It is a CNS myelin-associated neurite outgrowth inhibitor that is highly expressed in oligodendrocytes. Nogo-A is synthesized as an 1163 amino acid protein and lacks a signal peptide. Within conserved C-terminal reticulon homology domain (RHD), two transmembrane domains, which are separated by a 66 amino acid extracellular loop, exist. Both the N-terminal domain and the 66 amino acid domain (Nogo-66) can be detected on the cell surface and show neurite outgrowth inhibitory activity. The amino acid sequence of rat Nogo-A N-terminal domain is 76% identical to that of human Nogo-A. Within the RHD domain, rat Nogo-A shares 99% and 97% amino acid sequence identity with mouse and human Nogo, respectively.
Product Datasheets
Citations for Rat Nogo-A aa 2-172 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
5
Citations: Showing 1 - 5
Filter your results:
Filter by:
-
Plasticity-Enhancing Effects of Levodopa Treatment after Stroke
Authors: Daniela Talhada, Niklas Marklund, Tadeusz Wieloch, Enida Kuric, Karsten Ruscher
International Journal of Molecular Sciences
-
A proteolytic C-terminal fragment of Nogo-A (reticulon-4A) is released in exosomes and potently inhibits axon regeneration
Authors: Y Sekine, JA Lindborg, SM Strittmatt
Nat. Med., 2019-11-20;295(8):2175-2183.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Indomethacin protects rats from neuronal damage induced by traumatic brain injury and suppresses hippocampal IL-1beta release through the inhibition of Nogo-A expression.
J Neuroinflammation, 2012-06-07;9(0):121.
Species: Rat
Sample Types: Tissue Homogenates
Applications: Western Blot -
Oligodendrocyte-myelin glycoprotein and Nogo negatively regulate activity-dependent synaptic plasticity.
Authors: Raiker SJ, Lee H, Baldwin KT
J. Neurosci., 2010-09-15;30(37):12432-45.
Species: Mouse
Sample Types: Tissue Homogenates
Applications: Western Blot -
Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition.
Authors: Robak LA, Venkatesh K, Lee H, Raiker SJ, Duan Y, Lee-Osbourne J, Hofer T, Mage RG, Rader C, Giger RJ
J. Neurosci., 2009-05-06;29(18):5768-83.
Species: Rat
Sample Types: Tissue Homogenates
Applications: Western Blot
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsIsotype Controls
Reconstitution Buffers
Secondary Antibodies
Reviews for Rat Nogo-A aa 2-172 Antibody
There are currently no reviews for this product. Be the first to review Rat Nogo-A aa 2-172 Antibody and earn rewards!
Have you used Rat Nogo-A aa 2-172 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image